Compare BMEA & SOTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | SOTK |
|---|---|---|
| Founded | 2017 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.1M | 73.7M |
| IPO Year | 2021 | 1995 |
| Metric | BMEA | SOTK |
|---|---|---|
| Price | $1.27 | $5.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.83 | N/A |
| AVG Volume (30 Days) | ★ 566.6K | 43.0K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.19 | 37.50 |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $20,909,315.00 |
| Revenue This Year | N/A | $4.02 |
| Revenue Next Year | N/A | $10.95 |
| P/E Ratio | ★ N/A | $108.40 |
| Revenue Growth | N/A | ★ 1.97 |
| 52 Week Low | $0.87 | $3.23 |
| 52 Week High | $2.99 | $6.24 |
| Indicator | BMEA | SOTK |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 53.18 |
| Support Level | $1.21 | $4.69 |
| Resistance Level | $1.44 | $5.79 |
| Average True Range (ATR) | 0.06 | 0.35 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 58.14 | 52.53 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.